(R)-methyl 3-((tert-butoxycarbonyl)amino)-2,2-dimethylbutanoate | 499242-69-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (R)-methyl 3-((tert-butoxycarbonyl)amino)-2,2-dimethylbutanoate
• 英文别名: methyl (3R)-2,2-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate
• CAS: 499242-69-2
• 化学式: C₁₂H₂₃NO₄
• 分子量: 245.319
• InChiKey: XLJSFCCSXRZMHQ-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-methyl 3-((tert-butoxycarbonyl)amino)-2,2-dimethylbutanoate 在 盐酸 、 N-溴代丁二酰亚胺(NBS) 、 二乙胺基三氟化硫 、 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 四氯化碳 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.5h， 生成 (R)-methyl 2-(3-amino-2-methylbutane-2-yl)oxazole-4-carboxylate hydrochloride
  参考文献：
  名称：

  [EN] PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
  [FR] INHIBITEURS DE JAK3 DE TYPE PYRROLOPYRIDAZINE ET LEUR UTILISATION POUR TRAITER LES MALADIES INFLAMMATOIRES ET AUTO-IMMUNES

  摘要：

  揭示了式（I）的化合物及其药用盐。式（I）的化合物抑制JAK3的酪氨酸激酶活性，因此它们可用于治疗炎症和自身免疫性疾病。

  公开号：

  WO2012125887A1
• 作为产物：
  描述：

  2,2-二甲基乙酰乙酸甲酯 在 palladium 10% on activated carbon 氢气 、 四氯化钛 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 21.0h， 生成 (R)-methyl 3-((tert-butoxycarbonyl)amino)-2,2-dimethylbutanoate
  参考文献：
  名称：

  [EN] PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
  [FR] INHIBITEURS DE JAK3 DE TYPE PYRROLOPYRIDAZINE ET LEUR UTILISATION POUR TRAITER LES MALADIES INFLAMMATOIRES ET AUTO-IMMUNES

  摘要：

  揭示了式（I）的化合物及其药用盐。式（I）的化合物抑制JAK3的酪氨酸激酶活性，因此它们可用于治疗炎症和自身免疫性疾病。

  公开号：

  WO2012125887A1

文献信息

• PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
  申请人：Wrobleski Stephen T.

  公开号：US20140005146A1

  公开（公告）日：2014-01-02

  Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

  本发明揭示了式(I)化合物及其药学上可接受的盐。式(I)化合物抑制JAK3的酪氨酸激酶活性，因此它们可用于治疗炎症和自身免疫性疾病。
• Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases
  申请人：Wrobleski Stephen T.

  公开号：US09221826B2

  公开（公告）日：2015-12-29

  Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

  公开的是式(I)的化合物及其药学上可接受的盐。式(I)的化合物抑制JAK3的酪氨酸激酶活性，因此对治疗炎症和自身免疫性疾病有用。
• ——
  作者：Dieter Seebach、Thierry Sifferlen、Daniel J. Bierbaum、Magnus Rueping、Bernhard Jaun、Bernd Schweizer、Jacob Schaefer、Anil K. Mehta、Robert D. O'Connor、Beat H. Meier、Matthias Ernst、Alice Glättli

  DOI：10.1002/1522-2675(200209)85:9<2877::aid-hlca2877>3.0.co;2-w

  日期：2002.9

  The preparation of (S)-beta(2.2.3) -amino acids with two Me groups in the a-position and the side chains of Ala, Val, and Len in the P-position (double methylation of Boc-beta-HAla-OMe, Boc-beta-Val-OMe, and Boc-beta-LeuOMe, Scheme 2) is described. These beta-amino acids and unlabelled as well as specifically C-13- and (15)labelled 2,2-dimethyl-3-amino acid (beta(2.2)-HAib) derivatives have been coupled in solution (Schemes 1, 3 and 4) to give protected (N-Boc, C-OMe), partially protected (N-Boc/C-OH, N-H/C-OMe), and unprotected beta(2.2) - and beta(2.2.3)- hexapeptides, and beta(2.2) and beta(2.2.3)-heptapeptides 1-7. NMR Analyses in solution (Tables 1 and 2, and Figs. 2-4) and in the solid state (2D-MAS NMR measurements of the fully labelled BOC-(beta(2.2)-HAib)(6)-OMe ([C-13(30), N-15(6)]-1e; Fig. 5), and TEDOR/REDOR NMR investigations of mixtures (Fig. 6) of the unlabelled AC-([beta(2.2)-HAib)(7)- OMe (4) and of a labelled derivative ([C-13(4),N-15(2)]-5; Figs. 7- 11, and 19), a molecular-modeling study (Figs. 13 15), and a search in the Cambridge Crystallographic Data Base (Fig. 16) allow the following conclusions: i) there is no evidence for folding (helix or turn) or for aggregation to sheets of the geminally dimethyl substituted peptide chains in solution; ii) there are distinct conformational preferences of the individual beta(2.2) and beta(2.2.3)-amino acid residues: close to eclipsing around the C(O) - C(Me-2(CHR)) bond (tau(1.2)), almost perfect staggering around the C(2)-C(3) ethane bond (tau(2,3)), and antiperiplanar arrangement of H(C3) and H(N) (TIN; Fig. 12) in the solid state; iii) the beta(2,2)-peptides may be part of a turn structure with a ten-membered H-bonded ring; iv) the main structure present in the solid state of F3CCO(beta(2,2) -HAib)(7)-OMe is a nonfolded chain (>30 Angstrom between the termini and >20 Angstrom between the N-terminus and the CH2 group of residue 5) with all C = O bonds in a parallel alignment (+/-10degrees). With these structural parameters, a simple modelling was performed producing three (maybe four) possible chain geometries: one fully extended, two with parallel peptide planes (with zick-zack and crankshaft-type arrangement of the peptide bonds). and (possibly) a fourth with meander-like winding (D-G in Figs. 17 and 18).
• CD Spectra in Methanol ofβ-Oligopeptides Consisting ofβ-Amino Acids with Functionalized Side Chains, with Alternating Configuration, and with Geminal Backbone Substituents - Fingerprints of New Secondary Structures?
  作者：Dieter Seebach、Thierry Sifferlen、Pascal A. Mathieu、Andreas M. Häne、Christoph M. Krell、Daniel J. Bierbaum、Stefan Abele

  DOI：10.1002/1522-2675(20001108)83:11<2849::aid-hlca2849>3.0.co;2-r

  日期：2000.11.8

  beta -Hexa-, beta -hepta-, and beta -nonapeptides, 1-6, which carry functionalized side chains (CO(2)R, CO(2)(-), (CH(2))(4)NH(3)(+), CH(2)-CH=CH(2)) consisting of beta (3)-amino-acid residues of alternating configuration, or which carry geminal substituents in the 2- or 3-positions of all residues, have been synthesized (Schemes 1 - 3), and their CD spectra in MeOH are reported (Figs. 2 - 6). Strong Cotton effects (Theta >10(5)) are indicative of the presence of chiral secondary structures. It is suggested by simple modelling (Fig. 1) that the new beta -peptides should not be able to fold to the familiar 3(14)-helical structures. Still, three of them (3, 4, and 5) give rise to CD spectra matching those of beta -peptides that are known to be present as (M)- or (P)3(14)-helices in MeOH solution. While possible folding motifs (Figs. 3, b, and 7) of the new beta -peptides have been identified in crystal structures, an interpretation of the CD spectra has to be postponed until NMR solution structures become available. A list of all beta -peptides giving rise to CD spectra with a minimum near 215 nm is included (Table).
• US9221826B2
  申请人：——

  公开号：US9221826B2

  公开（公告）日：2015-12-29